Development of a decision flowchart to identify the patients need high-dose vancomycin in early phase of treatment

Table 3 Characteristics of patients classified in validation set

Characteristics	All patients (n = 126)	High-dose (n = 50)	Standard-dose (n = 76)	P value
Male, n (%)	74 (58.7)	25 (50.0)	49 (64.5)	0.331^d
Age [years]^a	57.8 ± 17.8	46.5 ± 14.6	65.1 ± 15.5	< 0.001^e
Body weight [kg]^a	56.6 ± 14.1	60.8 ± 15.1	53.9 ± 12.7	0.009^e
BMI [kg/m²]^a	21.5 ± 4.8	22.5 ± 5.7	20.9 ± 4.0	0.096^e
SCr [mg/dL]^a	0.63 ± 0.24	0.54 ± 0.20	0.69 ± 0.25	< 0.001^e
eCCr [mL/min]^a	109.6 ± 60.3	145.8 ± 56.4	85.9 ± 50.3	< 0.001^e
Initial VCM dose, n^b				< 0.001^d
> 2 g/day	19 (17/2/0)	16 (14/2/0)	3 (3/0/0)
=2 g/day	77 (0/77/0)	29 (0/29/0)	48 (0/48/0)
< 2 g/day	30 (2/23/5)	5 (1/4/0)	25 (1/19/5)
Days until first TDM [days]^c	3 (2–6)	3 (3–5)	3 (2–6)	0.962^f
First C_trough [μg/mL]^a
All patients	12.1 ± 5.4	8.5 ± 4.2	14.4 ± 4.8	< 0.001^e
> 2 g/day	13.6 ± 4.1	13.0 ± 4.0	16.8 ± 4.0	0.140^e
=2 g/day	11.6 ± 5.5	6.8 ± 2.1	14.6 ± 4.8	< 0.001^e
< 2 g/day	12.3 ± 5.7	4.6 ± 2.1	13.9 ± 4.9	< 0.001^e
BE conducted, n (%)	62 (49.2)	30 (60.0)	32 (42.1)	0.049^d

^aData are shown as mean ± standard deviation (SD)
^bNumbers in parentheses indicate the number of patients with dosing intervals of 8 h, 12 h, and others from the left, respectively
^cData are shown as median (range)
^dχ²-test
^eUnpaired student’s t-test
^fMann–Whitney U-test
BMI body mass index, SCr serum creatinine, eCCr estimated creatinine clearance, C_trough trough concentration of VCM, BE Bayesian estimation

ISSN: 2055-0294